Comparative Pharmacology
Head-to-head clinical analysis: ICATIBANT ACETATE versus QBRELIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ICATIBANT ACETATE versus QBRELIS.
ICATIBANT ACETATE vs QBRELIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of bradykinin B2 receptors, inhibiting bradykinin-mediated vasodilation, increased vascular permeability, and pain signaling. Also inhibits bradykinin-induced release of tissue plasminogen activator.
Angiotensin II receptor blocker; selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and decreased aldosterone secretion.
30 mg subcutaneous injection (pre-filled syringe) at the first sign of an acute attack; may repeat every 6 hours as needed, not to exceed 3 doses in 24 hours.
1 mg/kg intravenously or subcutaneously every 6 hours for acute attacks, maximum 3.3 mL per injection site.
None Documented
None Documented
Terminal elimination half-life approximately 1-2 hours in healthy adults, supporting intermittent intravenous dosing every 6 hours.
Terminal elimination half-life is approximately 10 hours (range 7-14 hours) in healthy adults; prolonged in renal impairment.
Primarily renal: 40% unchanged drug; 40% as inactive metabolites; biliary/fecal <10%.
Primarily renal (approximately 80%) with minimal biliary/fecal elimination (less than 5%).
Category C
Category C
Bradykinin B2 Receptor Antagonist
Bradykinin B2 Receptor Antagonist